Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
Background Anti(α)-programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy fails to provide durable clinical benefit for most patients with carcinoma. Recent studies suggested that strategies to reduce immunosuppressive cells, promote systemic T-cell responses and lymphocyte tra...
সংরক্ষণ করুন:
| প্রধান লেখক: | , , , , |
|---|---|
| বিন্যাস: | Artigo |
| ভাষা: | Inglês |
| প্রকাশিত: |
BMJ Publishing Group
2020-05-01
|
| মালা: | Journal for ImmunoTherapy of Cancer |
| অনলাইন ব্যবহার করুন: | https://jitc.bmj.com/content/8/1/e000493.full |
| ট্যাগগুলো: |
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|